Stocktoria

Coloplast A/S COLO-B.CO

DK · Nasdaq Copenhagen · XCSE · stock · Healthcare · website

Coloplast A/S financials (annual)

Revenue
kr 22.58B kr 24.50B kr 27.03B kr 28.94B 2022202320242026
Net income
kr 4.71B kr 4.78B kr 5.05B kr 3.07B 2022202320242026
Free cash flow
kr 3.96B kr 2.98B kr 1.42B kr 6.44B 2022202320242026

Bars are annual figures from 2022 to 2026; red bars are negative (a loss or cash outflow).

MetricFY2026FY2024FY2023FY2022
Revenuekr 28.9Bkr 27.0Bkr 24.5Bkr 22.6B
Gross profitkr 19.2Bkr 18.3Bkr 16.3Bkr 15.5B
R&D expensekr 1.1Bkr 913.0Mkr 872.0Mkr 866.0M
SG&A expensekr 10.8Bkr 10.1Bkr 8.6Bkr 7.8B
Operating incomekr 7.4Bkr 7.3Bkr 6.8Bkr 6.9B
Interest expensekr 658.0Mkr 795.0Mkr 638.0Mkr 172.0M
Income taxkr 775.0Mkr 1.3Bkr 1.2Bkr 1.4B
Net incomekr 3.1Bkr 5.1Bkr 4.8Bkr 4.7B
EPS (diluted)kr 13.64kr 22.46kr 22.20kr 22.11
Operating cash flowkr 8.0Bkr 2.8Bkr 4.2Bkr 5.1B
Free cash flowkr 6.4Bkr 1.4Bkr 3.0Bkr 4.0B
Cash & equivalentskr 511.0Mkr 788.0Mkr 911.0Mkr 414.0M
Inventorykr 4.1Bkr 3.7Bkr 3.5Bkr 3.2B
Goodwillkr 16.5Bkr 19.4Bkr 20.0Bkr 14.3B
Total assetskr 46.3Bkr 48.1Bkr 48.2Bkr 37.4B
Total debtkr 21.5Bkr 22.6Bkr 19.6Bkr 18.7B
Total liabilitieskr 32.0Bkr 30.1Bkr 30.9Bkr 29.2B
Shareholders' equitykr 14.3Bkr 17.9Bkr 17.3Bkr 8.3B
Share buybacks——kr 0kr 619.0M

Growth · year-over-year · Revenue CAGR 8.6%

MetricFY2026FY2024FY2023FY2022
Revenue growth+7.1%+10.3%+8.5%—
Net income growth-39.2%+5.6%+1.6%—
EPS growth-39.3%+1.2%+0.4%—
Free cash flow growth+353.2%-52.4%-24.7%—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · DK · as of 2026-09-30. Figures in DKK. Facts plus Stocktoria's own computed scores — not investment advice.